LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

Inicio・Lista de Acciones・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Abierto

SectorSanidad

525.22 -1.79

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

517.46

Máximo

543.36

Métricas clave
By Trading Economics
Ingresos	-72M -114M
Ventas	74M 287M
BPA	-4.956
Margen de beneficios	-39.75
Empleados	528
EBITDA	-75M -114M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+5.61% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.1B 11B
Apertura anterior	527.01
Cierre anterior	525.22

Noticias sobre sentimiento de mercado

By Acuity

28%

72%

81 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

263.2 / 277.1 Soporte y Resistencia

Madrigal Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 nov 2025, 23:59 UTC

Ganancias

Singtel's 1st Half Net Profit Surges

11 nov 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 nov 2025, 22:21 UTC

Ganancias

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 nov 2025, 23:52 UTC

Charlas de Mercado

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 nov 2025, 23:44 UTC

Ganancias

Singtel's 1H Net Profit Surges

11 nov 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 nov 2025, 23:18 UTC

Ganancias

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 nov 2025, 23:15 UTC

Ganancias

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 nov 2025, 23:14 UTC

Ganancias

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 nov 2025, 23:12 UTC

Ganancias

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 nov 2025, 23:11 UTC

Ganancias

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 nov 2025, 23:10 UTC

Ganancias

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 nov 2025, 23:04 UTC

Charlas de Mercado

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

11 nov 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Health Care Roundup: Market Talk

11 nov 2025, 21:46 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 nov 2025, 21:41 UTC

Ganancias

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 nov 2025, 21:40 UTC

Ganancias

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 nov 2025, 21:39 UTC

Ganancias

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 nov 2025, 21:39 UTC

Ganancias

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 nov 2025, 21:39 UTC

Ganancias

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 nov 2025, 21:38 UTC

Ganancias

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 nov 2025, 21:38 UTC

Ganancias

Aristocrat: Final Dividend 49 Australian Cents/Share

11 nov 2025, 21:37 UTC

Ganancias

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 nov 2025, 21:36 UTC

Ganancias

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 nov 2025, 21:35 UTC

Ganancias

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 nov 2025, 21:35 UTC

Ganancias

Alcon 3Q Adj EPS 79c >ALC

11 nov 2025, 21:35 UTC

Ganancias

Alcon 3Q Rev $2.61B >ALC.EB

11 nov 2025, 21:35 UTC

Ganancias

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 nov 2025, 21:35 UTC

Ganancias

Alcon 3Q EPS 48c >ALC.EB

Comparación entre iguales

Cambio de precio

Madrigal Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

5.61% repunte

Estimación a 12 Meses

Media 523.71 USD 5.61%

Máximo 590 USD

Mínimo 392 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

17 ratings

Comprar

Mantener

Vender

De acuerdo con 17 analistas que ofrecen calificaciones bursátiles a para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

263.2 / 277.1Soporte y Resistencia

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

81 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.